DATE: May 9th, 2017
TIME: 7:00AM PDT, 10:00AM ET, 2:00PM GMT
Early detection and elimination of new chemical entities with cardiac or hERG liability could substantially improve drug safety and minimize the cost of development. In this webinar, we will highlight different assays for validating ion channel inhibition using cell lines and cardiac toxicity using induced pluripotent stem cells (iPSCs).
High-throughput screening for in vitro potency evaluation of cardiac ion channel inhibitors on the FLIPR Tetra® System
- Optimize and validate a robust cell-based hERG fluorescence assay using the FLIPR® Potassium Assay Kit, a thallium-sensitive fluorescence dye to directly measure ion influx
- Run inhibition assays with voltage-gated sodium channels (NaV1.5) and L-type voltage-gated calcium channels (CaV1.2) using FLIPR® Membrane Potential Dye and FLIPR® Calcium 6 Dye, respectively
- Demonstrate high-throughput, early stage in vitro compound and potency assessment with comparable results from electrophysiological recording data
Multi-parameter in vitro assessment of compound effects on cardiomyocyte physiology using induced pluripotent stem cells
- Determine the effects of pharmacological compounds and other chemicals on the beating rate and profiles of cardiomyocytes using the FLIPR Tetra system and ImageXpress® Micro system. Assay data is characterized from 2D and 3D spheroid cardiomyocyte cultures. The assays employ calcium sensitive dyes to monitor changes in intracellular Ca2+ fluxes synchronous with cell beating which allows monitoring of beat rate, amplitude, and other parameters.
- Identify methods for multiparametric analysis and ranking of compounds for potential cardiotoxic hazards. This methodology is well suited for testing environmental chemicals and early safety testing in drug development prior to clinical studies.